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improved significantly and the use of DES were shown to be cost-effective. The
6-month total medical cost for DES and BMS were similar.
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READMISSION RATES AND COSTS ASSOCIATED WITH FIBRIN SEALANT USE
AMONG PATIENTS UNDERGOING ORTHOPEDIC SURGERY
Ye X1, Shah M2, Rupnow MF1, Hammond J1
1Ethicon, Inc., Somerville, NJ, USA, 2Xcenda, LLC., Palm Harbor, FL, USA
OBJECTIVES: Payers and hospital administrators are increasingly concerned about
readmission rates in surgical patients. We sought to examine the readmission
rates and hospital costs associated with EVICEL fibrin sealant (all-human formula-
tion), versus VITAGEL fibrin sealant (with bovine thrombin), or no adjunct hemo-
stat use for patients undergoing inpatient joint replacement surgeries.METHODS:
A retrospective analysis was conducted using Premier administrative data from
over 500UShospitals. Hospitalized patients (18 years)whounderwent orthopedic
surgery and received EVICEL, VITAGEL or no hemostat during surgery between
January 1, 2009 and November 30, 2009 were identified. A 1:1 (EVICEL:VITAGEL) and
1:3 (EVICEL: no hemostat) match was conducted using surgery type and propensity
scores of receiving EVICEL, based on patient and hospital characteristics via a
logistic regression model. The outcomes included 30-day all-cause readmission
rates and total index hospital costs. Differences in readmission rates were ana-
lyzed using conditional logistic regression. A generalized linear model with log-
link/gamma distribution was used for analyzing differences in total costs.
RESULTS: A total of 316 patients were identified (158 per cohort) for the EVICEL
versus VITAGEL and 1,808 patients for EVICEL (n452) versus no hemostat
(n1,356) analysis. Patients in the VITAGEL cohort were 6.8 times more likely to be
readmitted to the hospital compared to the EVICEL cohort (12.7% vs 3.8%; OR6.81,
95%CI 1.62, 28.66). Patients in the no hemostat cohort were 1.6 timesmore likely to
be readmitted compared to the EVICEL cohort. Total index hospital cost was lower
for the EVICEL cohort ($16,704) compared to VITAGEL cohort ($18,192 p0.001) on
average. The EVICEL cohort ($17,387) had similar total costs compared to no ad-
junct hemostat ($17,389) cohort. CONCLUSIONS: Readmission presents significant
costs and has been added to hospital quality measures. In this study, EVICEL was
associated with lower readmission rates compared to VITAGEL or no adjunct he-
mostat use in inpatient joint replacement surgeries.
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DIFFERENCES IN OUTCOMES MEASURES OF DIABETES PATIENTS USING AN
INSULIN DEVICE AND A CONVENTIONAL HUMAN INSULIN VIAL/SYRINGE
Baser O1, Wang L1, Yuce H2, Xie L1, Dysinger AH1
1STATinMED Research, Ann Arbor, MI, USA, 2New York City College of
Technology-CUNY/STATinMED Research, New York, NY, USA
OBJECTIVES: To compare the main outcomes differences including clinical events,
health care utilization and costs of patients using an insulin device for diabetes versus
patients using the conventional human insulin vial/syringe.METHODS: Using a ret-
rospective analysis of health insurance claims data between the years 2003 and 2008,
we identified patients with a diagnosis of diabetes and then divided them into an
insulindevice cohort andahuman insulinvial/syringe cohort, basedon their prescrip-
tion fills. Patients’ demographics, health care visits and costs were compared using
Chi-square testing and standardized differences. The 12-month follow-up clinical
event rates, health care facility use and costs for those patients were compared. Risk
adjustment was performed using the propensity score matching method with the
ProbChoice™algorithm.RESULTS:A total of 12,400 eligible patientswere identifiedas
using insulin for diabetes: 1,236 (9.97%) received the insulin device and 11,164 (90.03%)
received the insulin vial/syringe. Compared with patients who received the conven-
tionalhuman insulinvial/syringe, patients in the insulindevice groupwere likely tobe
younger, live in the Midwest of the United States, and have type I diabetes. Although
there were no significant differences in hypoglycemic events after risk adjustment,
patients in the insulin device group had significantly fewer cases of cerebrovascular
disease (4.14% vs. 9.12% p0.0055), congestive heart failure (7.18% vs. 12.15%
p0.0267) and chronic obstructive pulmonarydisease (4.70%vs. 10.50%p0.0039), but
more cases of dyslipidemia (68.51% vs. 54.42% p0.0002). Although the outpatient
costs for office visits ($1888 vs. $1895 p0.0257) were lower for patients on the insulin
device, their prescription costs ($5489 vs. $4635 p0.0001) were higher. The overall
risk-adjusted healthcare costs did not differ ($14,231 vs. $18,096 p0.1160) between
the two groups. CONCLUSIONS: Without significant addition to the costs, insulin
administration with the device is associated with fewer clinical events.
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POSITRON EMISSION TOMOGRAPHY SCREENING FOR LUNG CANCER: A
SYSTEMATIC REVIEW
Chien CR, Kao CH, Wang HN, Liang JA
China Medical University Hospital, Taichung, Taiwan
OBJECTIVES: There is no established effective lung cancer screening modality.
Positron Emission Tomography (PET) is helpful in lung cancer disease extent eval-
uation. The objective of our study is to evaluate the role of PET in lung cancer
screening via systematic review.METHODS: Using a strategy similar to a previous
computed tomography (CT) lung cancer screening systematic review [Black et al.
Thorax 2007;62:131–138], we searched for primary studies focusing on PET screen-
ing for lung cancer using the following keywords “(lung cancer) AND (positron
emission tomography) AND ((screen) OR (screening))” in Pubmed® on Nov 30th,
2010. Two reviewers (Chien C.R. & Wang H.N) reviewed all the identified studies
independently to find out studies compatible with our inclusion/exclusion criteria.
Further discussion with 3rd reviewer (Kao C.H.) was taken to reach conclusion
when there was any disagreement among the reviewers. Manual searching for
relevant studies was also performed from the included studies. We restricted our
analysis to non-overlapped studies published since 2000 and in English. RESULTS:
Among the identified studies (n2733), 239 studies were published before 2000,
2440 studies were excluded due to irrelevant titles and keywords, and another 34
studies were excluded after reviewing the abstracts. Full paper evaluation led to
further exclusion of 11 studies, and manual search led to inclusion of 2 additional
studies, leaving 11 studies for analysis. No studies evaluated the efficacy of primary
PET screening specific for lung cancer. Eight studies focused on primary PET
screening for cancer, and three studies reported finding in lung cancer CT screen-
ing programswith selective PET.CONCLUSIONS:The role of primary PET screening
for lung cancer remains unknown. PET has the potential to be used as a screening
modality not specific for lung cancer and as a selective modality in combination
with CT for lung cancer screening. [1] Black et al. Thorax 2007; 62:131-138
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ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF
QUALITY-ADJUSTED LIFE EXPECTANCY IN PATIENTS UNDER PROLONGED
MECHANICAL VENTILATION: A POPULATION-BASED STUDY DURING 1998-
2007 IN TAIWAN
Hung MC1, Wang JD2
1National Taiwan University, Taipei, Taiwan, 2National Cheng Kung University College of
Medicine, Tainan, Taiwan
OBJECTIVES:Thequality-adjusted life expectancy (QALE) and loss of quality-adjusted
life expectancy (loss of QALE) in patients under prolonged mechanical ventilation
(PMV) stratified by different underlying diseaseswere determined.METHODS:A sim-
ple randomsample of all 171, 635 patientswhowere performed continualmechanical
ventilation formore than21daysduring the1997-2007periods inTaiwan left us 50,481
subjects. After stratifying the patients according to specific diagnoses, we performed
latent class analysis (LCA) to categorize PMVpatientswithmultiple comorbidities into
several clustered groups. The survival functions were estimated for each group with
Kaplan-Meier method and extrapolated to 300months to obtain the life expectancies
through a semi-parametricmethod. The resultswere adjustedwith a utilitymeasure-
ment of quality of life to estimate the QALE (quality-adjusted life expectancies). Fur-
ther, we compared the age-, gender-matched reference populations to calculate the
loss of QALE.RESULTS: TheQALE of PMVpatientswith chronic renal failurewere 0.42
and 0.19 quality-adjusted life years (QALY) for consciousness clear versus unclear
states, respectively; those of patients with cancer were 0.48 and 0.22, respectively;
those of patients with Parkinson’s disease were 0.62 and 0.27, respectively; those of
patients with liver cirrhosis were 0.98 and 0.43 respectively; those of patients with
strokewere1.03and0.46 respectively; thoseofpatientswithdegenerativeneurological
diseases were 1.47and 0.64 respectively; those of patients with injuries and poisoning
were1.81 and 0.78 respectively. The LCA classified cases with multiple comorbidities
into several categories, of which therewas a consistent trend of decrease in QALE and
loss of QALE as people grow old. CONCLUSIONS: The results could hopefully reduce
thegapbetweenpatients’ familiesandhealthcareprovidersandassist theclinical and
health policy decisions.
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SCREENING TREATMENT AND CONTROL OF HYPERTENSION IN DIABETIC
PATIENTS USING OUTPATIENT VISIT DATA
Surbhi S, ML Mackey
St. John’s University, Queens, NY, USA
OBJECTIVES: Blood pressure control is a great challenge in the diabetic patient
population since the blood pressure target is lower, 130/80, as compared to
140/90 in general population. The objective of this study was to examine the rate
and the association of patient characteristics (demographic, access to health care
and clinical factors) and practice characteristics with hypertension screening,
treatment and control in diabetic population. METHODS: National Ambulatory
Medical Care Survey and the National Hospital Ambulatory Medical Care Survey
2006 were used to analyze outpatient visits made by adults18 years and older
diagnosed with diabetes. Descriptive analysis was done to find the rate and binary
logistic regression was carried out to find the predictors. Statistical significance
was set at alpha of 0.05. RESULTS: Hypertension screening, treatment and control
rate was 66.9%, 53.1% and 28.4% in diabetic patients. The odds of not getting
screenedwere visits other than primary care physician (OR7.52), with no diagnostic
tests (OR6.63), having no comorbidities (OR3.64), non obese (OR1.72) and increasing
age (OR2.03, OR2.35, OR2.72). Odds of not being treated were settings located in
south geographic region (OR1.29), provider other than primary care physician
(OR2.02), hospital setting (OR1.28), no diagnostic tests (OR1.97) and having no co
morbidities (OR1.558). Odds of not having blood pressure control were greater for
black race (OR 1.75), patients with no past visits (OR 1.79), obese (OR 1.37) and
having no co morbidities (OR 1.40). CONCLUSIONS: The study found that although
more than 50% of the diabetic patients were screened and treated, blood pressure
control was found in only one third of the population. Both the patient factors;
demographic, access to health care, clinical factors and practice characteristics
were responsible for poor quality of care (hypertension screening and treatment)
and poor outcome (blood pressure control).
Medical Device/Diagnostics – Cost Studies
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IDENTIFYING POTENTIAL DRIVERS OF COST SAVINGS WITH INSULIN
ADMINISTRATION DEVICES IN TYPE-2 DIABETES IN THE UNITED STATES
Pollock RF1, Curtis B2, Boye KS2, Timlin L3, Valentine WJ1
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OBJECTIVES: To investigate potential drivers of costs and cost savings when as-
sessing the budget impact of insulin administration devices (IADs) in patients with
type 2 diabetes (T2D).METHODS:AMicrosoft Excel®-basedmodel was constructed
to assess the budget impact of new reusable IADs in patients with T2D. The model
captured costs of insulin, IADs, needles, self-monitoring of blood glucose (test
strips and glucometers) and the direct medical costs of a number of diabetes com-
plications (minor and major hypoglycemia, myocardial infarction, stroke, end-
stage renal disease, blindness and amputation). Scenarios were constructed to
assess the budget impact of changes in hypoglycemia rates, compliance and insu-
lin wastage associated with a new IAD. The analyses were performed in a one
million member US healthcare plan from the payer perspective. Future costs were
discounted at 3%per annumand sensitivity analyseswere performed. RESULTS: In
a million member plan with a diabetes prevalence of 7.8% and annual diabetes
incidence of 0.52%, a hypothetical IAD capable of reducing hypoglycemia rates or
insulin wastage was projected to decrease healthcare expenditure over one and
five-year time horizons. Conversely, a hypothetical IAD capable of improving com-
pliance resulted in increased healthcare expenditure, driven by increased insulin
and needle costs. A device that conferred all of these benefits simultaneously was
found to be cost saving in the target population, resulting in a 0.62% decrease in
diabetes-related healthcare expenditure over five years. CONCLUSIONS: An IAD
capable of reducing hypoglycemic event rates and insulin wastage whilst improv-
ing compliance would likely be cost saving overall.
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GENDER DIFFERENCES IN TOTAL KNEE ARTHROPLASTY (TKA) POSTOPERATIVE
PAIN MANAGEMENT IN THE UNITED STATES
Graver RM1, Domyahn M1, Read CE1, Menzie AM1, Feinglass SR2
1Zimmer, Minneapolis, MN, USA, 2Zimmer, Warsaw, IN, USA
OBJECTIVES: The objective of this analysis was to highlight the differences in gen-
der pain management after a total knee arthroplasty in the United States.
METHODS:We identified 103,600 TKA procedures from the Thomson Reuters Mar-
ketScan® Commercial andMedicare Claim databases from January 1, 2003 through
June 30, 2009. For these procedures, we analyzed 873,237 pharmaceutical claims for
muscle relaxants and analgesics/antipyretics for the 12-month postoperative pe-
riod. The mean direct costs were calculated for each calendar year for gender
cohorts and not inflation-adjusted. Wilcoxon-Mann-Whitney tests were run for
each year to determine statistical significance among the gender cohorts.
RESULTS: During the analysis period, we found statistically significant differences
in pharmaceutical pain management spending between male and female cohorts.
The female cohort spending averaged $464 per patient for the 12-month postoper-
ative period compared to $364 for the male cohort. This represents a 27% differ-
ence. During this same period, the average number of pharmaceutical pain man-
agement claims per TKA decreased for all cohorts but these averages exhibited
convergence in 2008 as spending bymales increased slightly. CONCLUSIONS: Pub-
lished studies have failed to agree on the correlation between gender and postop-
erative pain. A recent postoperative pain study concluded that “gender was not
found to be a consistent predictor as traditionally believed©.” However, our retro-
spective analysis of actual claim data provides a statistically significant correlation
between female gender and increased consumption of postoperativemuscle relax-
ants and analgesics for total knee arthroplasty procedures. These data may help
surgeons provide appropriate postoperative care for their TKA patients. 1Ip, Hui
Yun Vivian, Et. al, Predictors of Postoperative Pain and Analgesic Consumption: A
Qualitative Systematic Review, Anesthesiology, September 2009:11(3)657-677.Mar-
ketScan® is a trademark of Thomson Reuters (Healthcare) Inc.
PMD13
POST INGUINAL HERNIA REPAIR PAIN MANAGEMENT COSTS: A STUDY USING
THE PREMIER PERSPECTIVE ™ DATABASE (PPD)
Morseon M, Hashemi L
Covidien, Franklin, MA, USA
OBJECTIVES: Several studies have reported on the ability to reduce post-operative
pain following Inguinal Hernia repair by self-fixating mesh. Our study examines
the overall cost increases when post operative pain following Inguinal Hernia Re-
pair is significant enough to be reported by an ICD-9 diagnosis code. METHODS:
The Premier Perspective™ Database (PPD) was used to track hospital costs associ-
atedwith an outpatient Inguinal hernia repair between January, 2008 through June,
2010. ICD-9 diagnosis codeswere used to further identify patient with the presence
of acute or chronic post operative pain. For post discharge painmanagement strat-
egies and costs we sponsored market research with 30 surgeons who perform
Inguinal Hernia repair surgery. Responses were collected to specific pain manage-
ment strategies employed, and average per patient costs when patient reported
pain was mild, moderate, and severe. RESULTS: A total of 51,108 patients under-
going outpatient Inguinal Hernia repair were identified in the PPD during our study
timeframe. An ICD-9 diagnostic code representing acute or chronic pain was pres-
ent in 228 discharges. The mean cost per discharge for patients with diagnosis of
acute/chronic pain was $3,309, compared to $2,910 for patients without the diag-
nostic of pain. Eighty percent of the physicians surveyed reported they would
prescribe pain therapy with a cost of less than $ 100.00. For moderate pain the
breakdown was 70% less than $100.00 and for severe pain 44% indicated the costs
would be less than $100.00. CONCLUSIONS: The management of pain following
Inguinal Hernia repair increase the pre- and post- discharge costs to the hospital,
insurers and patients. In addition, costs appear to increase in relation to the sever-
ity of the pain reported. Inguinal hernia repair techniques which result in reduced
post operative pain such as using self fixating mesh have the potential to reduce
the costs associated with Inguinal Hernia repair.
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COMPARISON OF PER DISCHARGE COSTS OF THE REPAIR OF
INCISIONAL/VENTRAL HERNIAS PERFORMED WITH PERMACOL™ AND
STRATTICE™ IN THE UNITED STATES
Morseon M, Hashemi L
Covidien, Franklin, MA, USA
OBJECTIVES: Biologic graft implants are used in the repair of complex Incisional/
Ventral hernias when in the surgeon’s judgment the complexity of the hernia
and/or the patient’s risk factors indicate a biologic material provides an opportu-
nity for better outcomes than repair performedwith syntheticmeshmaterials. Our
objective was to examine the average cost per discharge of Incisional/Ventral her-
nia repair when Permacol™ and Strattice™ biological meshes were used.
METHODS: The Premier Perspective™ Database (PPD) was used to track hospital
reported costs associated with patient stays for Incisional/Ventral hernia repair
utilizing Permacol™ and Strattice™ in the 27 months from April, 2008 through
June, 2010. PPD is the largest hospital-based, service-level comparative database in
the USA providing detailed resource utilization and cost data categorized under a
patients’ principal and secondary procedure codes. ICD-9 procedure codes were
used to identify patients with Incisional/Ventral hernia repair. RESULTS: A total of
36,105 patients with a primary procedure code for Incisional/Ventral hernia repair
were identified between April, 2008 through June, 2010. Biologics were used in 4.2%
of these patients. Permacol™was used 135 patients and Strattice™was used in 287
patients. There were no significant differences in patient’s demographics between
the two groups. Mean and median cost per discharge was lower for Permacol™
cases compared to Strattice™ ($19,221 vs. $22,428 formean and $3,163 vs. $5,102 for
median). Cost of “Central Supply” accounted for approximately 50% of the overall
cost in both groups, while “Room and Board” accounted for approximately 22% of
the overall cost. CONCLUSIONS: The mean cost of the biologic implant was re-
ported as 42% higher when Strattice™ was used vs when Permacol™ was used
($6,596 vs. $4,659) in Incisional/Ventral hernia repairs. The mean overall discharge
costs was 17% higher when Strattice™ was used vs Permacol™ ($22,428 vs.
$19,221).
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ECONOMIC EVALUATION OF SELF-MONITORING OF BLOOD GLUCOSE REGIMES
PLUS CONVENTIONAL PHARMACOLOGIC TREATMENT FOR TYPE-2 DIABETIC
PATIENTS IN MEXICO: ESTIMATION BY DISCRETE EVENT SIMULATION
Zanela OO1, Cabra HA1, Muñoz DF2
1Johnson & Johnson Medical, Mexico City, D.F., Mexico, 2Instituto Tecnológico Autónomo de
México, Mexico City, D.F., Mexico
OBJECTIVES: Estimate the yearly costs attributable to and resulting from the pro-
vision of different self-monitoring of blood glucose (SMBG) regimes vs. no SMBG in
the treatment of patients with type-2 diabetes (T2D) from the Mexican public
health system perspective.METHODS: The individual experience of a patient with
T2D was simulated using a discrete event simulation built in Arena™. Patients
were created with unique, randomly assigned clinical, epidemiologic and demo-
graphic baseline characteristics, cloned 3 times, and sent to each of the SMBG
regimes considered (0, 1, 2 and 3 times daily). Clinical guidelines (ADA, ALAD) were
used to determine diabetic- and complication-specific pharmacologic treatment,
resource utilization and treatment algorithms & goals. Glycosilated hemoglobin
(HbA1c) was the main driver of disease progression, determining initial state, drug
titulation/combinations and insulin dosage. Treatment therapies include lifestyle
modifications alone, oral antidiabetics (OADs) and insulin use. Complication and
acute event development for each SMBG regime was assessed through relative
risks, taken from local published studies. All OADs and insulins were assumed to
be equally effective in reducing HbA1c. T2D-related complications and mortality
were considered. All clinical and cost datawere obtained frompublished literature.
Simulation was run with 16,000 patients for 20 years using a 4.5% annual discount
rate. Per-patient costs for selected years are shown in inflation-adjusted 2010MXP.
RESULTS: 1, 2 and 3 times daily SMBG regimes resulted in lesser costs than no
SMBG after years 1, 3 and 4, respectively. Year 5 accumulated costs for the former
were $114,099, $108,152 and $110,898, and $120,723 for no SMBG. CONCLUSIONS:
SMBG adoption yields better mid- and long-run clinical and economic outcomes
than no SMBG. Potential savings are due to fewer complications and slower disease
progression. Healthcare institutions should adopt SMBG to control HbA1c levels
and reduce the social and economic burden T2D imposes.
PMD16
COMPARISON OF COST AND CLINICAL OUTCOMES OF OPEN VERSUS
LAPAROSCOPIC THORACIC PROCEDURES IN THE UNITED STATES
Hashemi L1, Minshall ME2
1Covidien, Franklin, MA, USA, 2Covidien, Mansfield, MA, USA
OBJECTIVES: Laparoscopic thoracic procedures have often been associated with
shorter hospitalizations. However, the economic impact of laparoscopic thoracic
procedures compared to open thoracic procedures have not been fully assessed. In
this study, we examined the differences in cost and hospital length of stay for open
versus laparoscopic thoracic procedures in the United States.METHODS: The Pre-
mier Perspective™ Database (PPD) was used to estimate the incidence and costs of
laparoscopic versus open thoracic procedures in the United States. PPD is the larg-
est hospital-based database in the USA providing detailed resource utilization and
cost data. Patients with principal procedure codes for open or laparoscopic proce-
dures between January 1, 2007 through December 31, 2009 were selected. Combi-
nations of ICD-9 diagnosis codes and CPT procedure codes were used to identify
surgical site infections, hemorrhage and blood transfusions. RESULTS: A total of
22,640 patients with a primary procedure code for thoracic procedures were iden-
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